

SHORT REPORT

Open Access



# Near-ubiquitous presence of a vancomycin-resistant *Enterococcus faecium* ST117/CT71/*vanB* –clone in the Rhine-Main metropolitan area of Germany

Linda Falgenhauer<sup>1</sup>, Moritz Fritzenwanker<sup>1</sup>, Can Imrzaoglu<sup>1</sup>, Katrin Steul<sup>2</sup>, Marlene Scherer<sup>2</sup>, Rhine-Main VREfm study group, Ursel Heudorf<sup>2\*†</sup> and Trinad Chakraborty<sup>1\*†</sup>

## Abstract

Whole-genome sequencing analysis of Vancomycin-resistant *Enterococcus faecium* isolates from the Frankfurt metropolitan region revealed that 78/94 isolates were MLST type ST117, cgMLST complex type CT71 with a common *vanB* chromosomal insertion site. This indicates circulation of a single VRE clone in a catchment area of 5,000-km<sup>2</sup> with 3 million inhabitants.

**Keywords:** VRE, ST117, cgMLST, WGS

## Background

Vancomycin-resistant *Enterococcus faecium* (VREfm) are an important cause of nosocomial infections worldwide [1]. The WHO ranks VREfm on its high priority list of multidrug-resistant microorganisms because of increasing prevalence and transmission rates in community and healthcare settings [2]. Since 2014 there has been a dramatic increase of VREfm prevalence among clinical samples in Germany. Marked regional differences have been noted, with high VREfm prevalence within an east-west axis in central Germany (“VRE-belt”), that includes the German federal state of Hesse [3, 4].

The presence and impact of epidemic VREfm on individual patients entering the healthcare system particularly within the “VRE-belt” is poorly understood. Here we report on the genome-based analysis and comparison of VREfm isolated from patients with or without a prior history of hospitalization during admission to intensive

care units or other wards with patients at risk for VREfm colonization/infection i.e. hemato-oncological and transplantation units.

## Sampling area, patient characteristics

Sampling was performed between November 2017 and June 2018 in 17 hospitals within the Frankfurt am Main metropolitan region, all of whom are members of the Network on multidrug-resistant organisms in the Rhine-Main area (MDRO Network Rhine-Main). The size of hospitals varied between 100 and 1488 beds. Among these, 11/17 were tertiary care hospitals, while the remaining six hospitals were either standard care ( $n = 3$ ), general hospitals ( $n = 2$ ) or a specialized clinic ( $n = 1$ ) (Additional file 1: Table S1). Participating hospitals were requested to provide VREfm isolates from samples obtained from patients at admission (within 72 h) to intensive care units or other wards where patients with a high risk for VREfm colonization/infection were treated, i.e. hemato-oncological and transplant units ( $n = 85$ , anal/rectal swabs, stool specimens). An active admission screening of all patients or of defined risk patients was not performed in this study. Hence, determining the prevalence of VRE carriage at admission was not the purpose of this study. The number of isolates per hospital (Additional file 1: Table S1) was dependent on the

\* Correspondence: [ursel.heudorf@gmx.de](mailto:ursel.heudorf@gmx.de); [Trinad.Chakraborty@mikrobio.med.uni-giessen.de](mailto:Trinad.Chakraborty@mikrobio.med.uni-giessen.de)

†Ursel Heudorf and Trinad Chakraborty are senior authors that contributed equally to this article.

<sup>2</sup>Rhine-Main- Network on MDRO (multidrug-resistant organisms), Breite Gasse 28, 60313 Frankfurt/Main, Germany

<sup>1</sup>Institute of Medical Microbiology, Justus Liebig University Giessen and German Center for Infection Research (DZIF), Partner Site Giessen-Marburg-Langen, Schubertstrasse 81, 35392 Giessen, Germany



size of the catchment area of the respective hospital. For hospitals that did not have the requested amount of VREfm-positive screening samples within the study period, VREfm from clinical samples were included ( $n = 10$ ). These comprised of isolates from blood cultures, urine, wound smears, intra-abdominal surgery smears and a central venous catheter isolate. Identification and antibiotic resistance determination of VREfm was performed using standard laboratory methods and technologies (e.g. chromID VRE plates, MALDI MS, VITEK II, BioMérieux, Nürtingen, Germany) in the labs providing regular microbiological service for the participating hospitals.

In total, VREfm isolates from 95 patients were included. Patient meta-data was collected using a questionnaire (Table 1).

**Table 1** Depiction of the patient meta-data

Parameter		n	%
Sex	Male	54	56.8
	Female	41	43.2
Age	<60	15	15.8
	60- < 70	21	22.1
	70- < 80	29	30.5
	> 80	29	30.5
	Not reported	1	1.1
Underlying disease	Hemato/oncology	19	20.0
	Cardiology	19	20.0
	Other	36	37.9
	Not reported	21	22.1
Travel abroad during the last 12 months	None	45	47.4
	Yes	8	8.4
	Indeterminate	42	44.2
Previous hospital stays within the last 12 month	No	13	13.6
	Yes	76	80.0
Previous antimicrobial therapy*	Not ascertainable	6	6.3
	Vancomycin	9	9.5
	Teicoplanin	6	6.3
	Piperacillin/Tazobactam	25	26.3
	Carbapenem	19	20.0
	Cephalosporin	20	21.1
	Penicillin	12	12.6
	Metronidazole	12	12.6
	Quinolone	17	17.9
	Treated with antibiotics	72	75.8
No antibiotic treatment	2	2.1	
	Not reported	21	22.1

\*multiple answers were possible

The mean age of the patients was  $71.2 \pm 14.6$  years, and ranged from a new-born to 95 years old. Fifty-four patients were male and 41 female. Information regarding a previous hospital stay during the last 12 months was reported in 93.6% (89/95) of the patients. Of these, 85% (76/89) reported a hospital stay. An underlying disease was reported in 77.9%. For 72/95 patients, an antimicrobial therapy during the past 12 months was recorded. Prior treatment with vancomycin was reported in 9.5%. VREfm was a first-time detection in 81 patients. Pre-existing VREfm carriage was known in 14 cases prior to the study.

### Characteristics of the VREfm isolates


VREfm were isolated and tested for susceptibility by the participating MDRO Network Rhine-Main centres using standard procedures for clinical diagnostic laboratories. VREfm isolates were generally were ampicillin-, fluoroquinolone- and carbapenem-resistant and linezolid-susceptible.


Whole genome sequencing (WGS) was performed as reported earlier [5, 6]. Resistance gene prediction, and Multilocus sequence typing (MLST) was performed using goseqit tools (<https://www.goseqit.com/>, Additional file 2: Table S2). Ninety-three VREfm harbored *vanB*, and a single isolate harbored *vanA*. One isolate did not harbor any *van* gene and was excluded from further analysis.

Analysis of the virulence genes was performed using goseqit tools. The presence of the enterococcal surface protein Esp required for promoting biofilm formation (Additional file 2: Table S2), and the PTS<sub>clin</sub> phosphotransferase system associated with colonization potential of clinical isolates [7] as well as the uptake and utilization of amino sugars such as  $\beta$ -N-acetylglucosamine commonly found in mucin on the surfaces of epithelial cells and in biofilms were detected using blastn [8]. All *van*-encoding isolates harbored the *efAfm* gene, suggested to be involved in cell wall adherence, which is concordant with the results from earlier studies [9]. Ninety-two isolates harbored the *hlyEfm*, *acm* and PTS<sub>clin</sub>, while 90/94 isolates carried the *esp* gene.

Almost all isolates (90/94), regardless of source, were ST117 with the remaining four isolates each representing ST80, ST192, ST262 and ST1428. The ST262 isolate harbored a *vanA* gene.

The use of MLST-based data to classify VREfm is controversial because of its high recombination rates that masks relatedness of otherwise highly related strains. Therefore, further differentiation of the ST117 isolates using a core-genome MLST (cgMLST) was performed (Ridom SeqSphere+ 5.1.0., Ridom GmbH, Münster, Germany; *Enterococcus faecium* scheme [10]). This analysis revealed that 78/90 (87%) of the ST117 isolates, i.e. from both non-clinical as well as clinical samples, were all members of a single cgMLST complex type (CT71, Fig. 1). Minor CTs detected in ST117 isolates were CT469 ( $n = 4$ ),





hospital before more than 12 months ago, a nosocomial acquisition during the current hospital stay, or an acquisition through the dissemination of this clone in communal spaces outside of healthcare institutions. Further studies are required to answer the questions raised here, with particular focus on the presence of this clone in the community, healthcare-independent populations and other reservoirs (livestock, food, water).

### Conclusion

We report the detection of a near-ubiquitous VREfm clone (ST117/CT71/*vanB*) circulating within the metropolitan region in and around Frankfurt am Main/Germany. The presence both of a single clone in such a large catchment area and the detection of a possible

multi-hospital VRE transmission in this study has only been revealed as a result of WGS-based analysis. As vancomycin resistance is associated with enhanced mortality among patients in hospital settings, in particular bloodstream infections [16, 17], the prevention of VREfm infections is a major objective. The presence of a VREfm clone within different institutions questions whether infection control and antimicrobial stewardship interventions can be effective without an understanding of the VREfm carriage state and transmission dynamics in human populations within the catchment area studied. The results of our study call for the establishment of a multihospital infection control approach, including rapid detection tools to identify predominant clones and for a genome-based long-term surveillance to be able to

detect newly emerging clones. In addition, the use of clone-based strategies for eradication i.e. based on vaccines or bacteriophages, would be interesting avenues for further pursuit.

## Additional files

**Additional file 1: Table S1.** Characteristics of the sequenced isolates. Depicts the characteristics of each VREfm isolate presented in this study. (DOCX 14 kb)

**Additional file 2: Table S2.** Characteristics of the participating hospitals. Depicts selected characteristics of the hospitals participating in the study. (DOCX 30 kb)

**Additional file 3: Table S3.** Statistical analysis of parameters associated with ST117/CT71/vanB clone carriage. Depicts the statistical analysis of parameters associated with the carriage of the ST117/CT71/vanB clone. (DOCX 12 kb)

**Additional file 4: Table S4.** Information on previous hospital stays of the patients. Depicts previous hospital stays of the patients, including information in which hospitals they previously resided. (DOCX 17 kb)

**Additional file 5: Figure S1.** Regional distribution of the Cluster 1 VREfm ST117/CT71/vanB isolates. Depicts the regional distribution of Cluster 1 VREfm ST117/CT71/vanB isolates. Districts may include more than one hospital. The original map was extracted from Googlemaps (<https://www.google.de/maps/@50.2354853,8.7072805,11z>). (PDF 2079 kb)

**Additional file 6: Figure S2.** Interaction map between the different participating hospitals. Indicates the patients' previous hospital history, wherever known. Connections between hospitals mark previous hospital stays in another hospital, while circles indicate a previous stay in the same hospital. (PDF 15 kb)

## Abbreviations

cgMLST: Core genome multilocus sequence typing; CT: Complex type; MDRO: Multidrug-resistant organisms; MLST: Multilocus sequence typing; ST: Sequence type; VRE: Vancomycin-resistant enterococci; VREfm: Vancomycin-resistant *Enterococcus faecium*; WGS: Whole-genome sequencing; WHO: World Health Organization

## Acknowledgements

We thank all clinics for participating in the study, for collection of the isolates. We thank Christina Gerstmann (Institute of Medical Microbiology, Giessen, Germany) for excellent technical assistance. We are indebted to Paul Higgins (Institute of Medical Microbiology, Immunology and Hygiene, University of Cologne, Cologne, Germany) for help with the cgMLST typing. The members of the Rhine-Main VREfm study group are the following (alphabetical order): Sabine Albert-Braun<sup>1</sup>, Klaus-Peter Hunfeld<sup>2</sup>, Volkhard Kempf<sup>3</sup>, Andreas Kneifel<sup>4</sup>, Adnan Kukic<sup>5</sup>, Bernhard Jahn-Mühl<sup>6</sup>, Katharina Madlener<sup>7</sup>, Klaus Oberdorfer<sup>8</sup>, Jörn-Peter Oeltze<sup>9</sup>, Jörg Schulze<sup>10</sup>, Navid Sotoudeh<sup>11</sup>, Rolf Tessmann<sup>12</sup>.

Author affiliations of study group members:

<sup>1</sup> Klinikum Frankfurt Höchst, Frankfurt/Main, Germany.

<sup>2</sup> Institute for Laboratory Medicine, Microbiology & Infection Control, North West Medical Centre, Frankfurt/Main, Germany.

<sup>3</sup> University Hospital, Goethe University, Frankfurt/Main, Germany.

<sup>4</sup> Klinikum Hanau, Hanau, Germany.

<sup>5</sup> Hochtaunuskliniken, Bad Homburg, Germany.

<sup>6</sup> AGAPLESION HYGIENE, Frankfurter Diakonie Kliniken, Frankfurt/Main, Germany.

<sup>7</sup> Kerckhoff Klinik, Bad Nauheim, Germany.

<sup>8</sup> MVZ Labor Dr. Limbach & Kollegen GbR, Heidelberg, Germany.

<sup>9</sup> DKD HELIOS Klinik, Wiesbaden, Germany.

<sup>10</sup> Sana Klinikum, Offenbach, Germany.

<sup>11</sup> Krankenhaus Bad Soden, Bad Soden, Germany.

<sup>12</sup> Berufsgenossenschaftliche Unfallklinik, Frankfurt/Main, Germany.

Email addresses of study group members

• [Sabine.Albert-Braun@KlinikumFrankfurt.de](mailto:Sabine.Albert-Braun@KlinikumFrankfurt.de)

• [hunfeld.klaus-peter@khnw.de](mailto:hunfeld.klaus-peter@khnw.de)

• [volkhard.kempf@kgu.de](mailto:volkhard.kempf@kgu.de)

- [andreas\\_kneifel@klinikum-hanau.de](mailto:andreas_kneifel@klinikum-hanau.de)
- [adnan.kukic@hochtaunus-kliniken.de](mailto:adnan.kukic@hochtaunus-kliniken.de)
- [Bernhard.Jahn@agaplesion.de](mailto:Bernhard.Jahn@agaplesion.de)
- [kmadlemer@kerckhoff-klinik.de](mailto:kmadlemer@kerckhoff-klinik.de)
- [klaus.oberdorfer@labor-limbach.de](mailto:klaus.oberdorfer@labor-limbach.de)
- [joern-peter.oeltze@helios-kliniken.de](mailto:joern-peter.oeltze@helios-kliniken.de)
- [joerg.schulze@sana.de](mailto:joerg.schulze@sana.de)
- [nshotudeh@kliniken-mtk.de](mailto:nshotudeh@kliniken-mtk.de)
- [rolf.tessmann@bgu-frankfurt.de](mailto:rolf.tessmann@bgu-frankfurt.de)

## Authors' contributions

UH and TC implemented the study. KS, MS and Rhine-Main VREfm study group provided isolates and gathered information. LF, MF, CI, UH, TC gathered and analyzed the data. TC, UH and LF wrote the manuscript, which all authors approved.

## Funding

This work was supported by grants from the Bundesministerium fuer Bildung und Forschung (BMBF, Germany) within the German Center for Infection research (DZIF/grant number 803280811 to TC). Support was also obtained from the Hessian Ministry of Social Affairs and Integration for the MDRO Network Rhine-Main and the Hessian Ministry of Higher Education, Research and Arts within the project HuKKH (Hessisches universitaeres Kompetenzzentrum Krankenhaushygiene).

## Availability of data and materials

The raw sequencing data are available in ENA under the accession number PRJEB29744.

## Ethics approval and consent to participate

The study was approved by the ethics committee of the medical faculty of the Justus-Liebig-University of Giessen (AZ: 179/16). All samples were taken as part of standard care procedures.

## Consent for publication

Not applicable (no individual person's data included).

## Competing interests

The authors declare that they have no competing interests.

Received: 22 March 2019 Accepted: 9 July 2019

Published online: 29 July 2019

## References

1. Gilmore MS, Clewell DB, Ike Y, Shankar N. Enterococci: from commensals to leading causes of drug resistant infection [internet]. Gilmore MS, Clewell DB, Ike Y, Shankar N, editors. Boston, Massachusetts, USA: Massachusetts Eye and Ear Infirmary; 2014. Available from: <https://www.ncbi.nlm.nih.gov/books/NBK190426/>
2. Tacconelli E, Carrara E, Savoldi A, Harbarth S, Mendelson M, Monnet DL, et al. Discovery, research, and development of new antibiotics: the WHO priority list of antibiotic-resistant bacteria and tuberculosis. Lancet Infect Dis [Internet]. Elsevier; 2018 [cited 2018 Oct 1];18:318–27. Available from: <https://www.sciencedirect.com/science/article/pii/S1473309917307533?via%3Dihub>
3. Gastmeier P, Schröder C, Behnke M, Meyer E, Geffers C. Dramatic increase in vancomycin-resistant enterococci in Germany. J Antimicrob Chemother. 2014;69:1660–4.
4. Remschmidt C, Schröder C, Behnke M, Gastmeier P, Geffers C, Kramer TS. Continuous increase of vancomycin resistance in enterococci causing nosocomial infections in Germany –10 years of surveillance. Antimicrob Resist Infect Control Antimicrobial Resistance & Infection Control; 2018;7.
5. Fritzenwanker M, Imirzalioglu C, Gentil K, Falgenhauer L, Wagenlehner FME, Chakraborty T. Incidental detection of a urinary *Escherichia coli* isolate harbouring *mcr-1* of a patient with no prior history of colistin treatment. Clin Microbiol Infect [Internet] Elsevier Ltd; 2016;22:954–5. Available from: <https://doi.org/10.1016/j.cmi.2016.08.027>.
6. Falgenhauer L, Imirzalioglu C, Ghosh H, Gwozdzinski K, Schmiedel J, Gentil K, et al. Circulation of clonal populations of fluoroquinolone-resistant CTX-M-15-producing *Escherichia coli* ST410 in humans and animals in Germany. Int J Antimicrob Agents [Internet]. Elsevier; 2016 [cited 2016 May 17];47:457–

65. Available from: <http://www.ijaaonline.com/article/S0924857916300863/fulltext>
7. Zhang X, Top J, De Been M, Bierschenk D, Rogers M, Leendertse M, et al. Identification of a genetic determinant in clinical *Enterococcus faecium* strains that contributes to intestinal colonization during antibiotic treatment. *J Infect Dis.* 2013;207:1780–6.
8. Altschul SF, Gish W, Miller W, Myers EW, Lipman DJ. Basic local alignment search tool. *J Mol Biol* [Internet]. 1990 [cited 2014 Jul 10];215:403–10. Available from: <http://www.ncbi.nlm.nih.gov/pubmed/2231712>
9. Soheili S, Ghafourian S, Sekawi Z, Neela V, Sadeghifard N, Ramli R, et al. Wide distribution of virulence genes among *Enterococcus faecium* and *Enterococcus faecalis* clinical isolates. Hindawi Publishing Corporation; 2014; 2014. Available from <https://doi.org/10.1155/2014/623174>.
10. de Been M, Pinholt M, Top J, Bletz S, Mellmann A, van Schaik W, Brouwer E, Rogers M, Kraat Y, Bonten M, Corander J, Westh H, Harmsen D, Willems JLR, Carroll KC. Core Genome Multilocus Sequence Typing Scheme for High-Resolution Typing of *Enterococcus faecium*. *Journal of Clinical Microbiology.* 2015;53(12):3788–97.
11. Bender JK, Kalmbach A, Fleige C, Klare I, Fuchs S, Werner G. Population structure and acquisition of the *vanB* resistance determinant in German clinical isolates of *Enterococcus faecium* ST192. *Sci Rep* [Internet] Nature Publishing Group; 2016;6:1–13. Available from: <https://doi.org/10.1038/srep21847>.
12. Mann H, Whitney D. On a test of whether one of two random variables is stochastically larger than the other. *Ann Math Stat.* 1947;18:50–60.
13. Werner G, Coque TM, Hammerum AM, Hope R, Hrynowicz W, Johnson A, et al. Emergence and spread of vancomycin resistance among enterococci in Europe. *Eurosurveillance.* 2008;13.
14. Mutters NT, Mersch-Sundermann V, Mutters R, Brandt C, Schneider-brachert W, Frank U. Control of the spread of vancomycin- resistant enterococci in hospitals epidemiology and clinical relevance. *Dtsch Arztebl Int.* 2013;110: 725–31.
15. Klare I, Bender JK, Koppe U, Abu Sin M, Eckmanns T. Eigenschaften, Häufigkeit und Verbreitung von Vancomycin- resistenten Enterokokken (VRE) in Deutschland – Update 2015/2016. *Epidemiol Bull.* 2017;519–27.
16. Weber S, Hogardt M, Reinheimer C, Wichelhaus TA, Kempf VAJ, Kessel J, et al. Bloodstream infections with vancomycin-resistant enterococci are associated with a decreased survival in patients with hematological diseases. *Ann Hematol Annals of Hematology.* 2019;98:763–73.
17. Prematunge C, Macdougall C, Johnstone J, Adomako K. VRE and VSE bacteremia outcomes in the era of effective VRE Therapy: a systematic review and meta-analysis. *Infect Control Hosp Epidemiol.* 2016;37:26–35.

## Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Ready to submit your research? Choose BMC and benefit from:

- fast, convenient online submission
- thorough peer review by experienced researchers in your field
- rapid publication on acceptance
- support for research data, including large and complex data types
- gold Open Access which fosters wider collaboration and increased citations
- maximum visibility for your research: over 100M website views per year

At BMC, research is always in progress.

Learn more [biomedcentral.com/submissions](http://biomedcentral.com/submissions)

